

29 January 2024

Osteopore achieves milestone of 100,000 implants globally

Highlights

- Osteopore achieves a significant milestone in its commercialisation journey with more than 100,000 implants globally.
 - This achievement sets Osteopore on a platform for growing and continuing success in its commercialisation journey.
-

Osteopore Limited (ASX: OSX; Osteopore or Company), a global regenerative medicine company founded in Singapore and listed in Australia, is delighted to announce that it has achieved a significant milestone of more than 100,000 implants globally; almost 80% of these 100,000 implants are achieved on the back of its commercialisation efforts over the last 4 years (2019-2023).

Osteopore actively commercialised its technology from September 2019, and has grown its product adoption steadily despite global headwinds such as the pandemic, poor macroeconomic conditions (2022-2023), and a major overhaul in the European regulatory environment.

Osteopore's products and technology are clinically validated for its safety and performance in more than 30 clinical publications¹. Its products are supported through reimbursement by the most prominent medical scheme in South Africa, Discovery Health Medical Scheme², leading to a year-on-year doubling in sales in the country³.

¹ Refer to ASX announcement dated 1 August 2023 "Investor Presentation"

² Refer to ASX announcement dated 16 May 2023 "Largest South African Medical Insurer provides cover for OSX"

³ Refr to ASX announcement dated 31 October 2023 "Activities Update Qtr Ending September 2023 and Appendix 4C"



Commenting on Osteopore's achievement, Osteopore CEO Jing Lim said:

"First and foremost, we would like to thank all surgeons for being on the journey with us, adopting the use of scaffolds that are designed on the concept of tissue engineering to improve clinical outcomes. We would also like to thank our patients for their trust and confidence in our product and technology.

Secondly, this 100,000-implant milestone has demonstrated the commercial viability of our product and technology. Our organisation is humbled and motivated to accelerate our commercialisation process so that more surgeons and patients around the world can have access to technology that improves outcomes."

ENDS

This announcement dated 29 January 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: mark_leong@osteopore.com**Isaac Stewart**

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: istewart@canningspurple.com.au**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia aiming to commercialise products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time only to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.



Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

